Predicting Placenta Accreta Spectrum Disorders in a Cohort of Pregnant Patients in the North-East Region of Romania—Diagnostic Accuracy of Ultrasound and Magnetic Resonance Imaging
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Jauniaux, E.; Collins, S.; Burton, G.J. Placenta accreta spectrum: Pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am. J. Obstet. Gynecol. 2018, 218, 75–87. [Google Scholar] [CrossRef] [Scilit]
- Luke, R.K.; Sharpe, J.W.; Greene, R.R. Placenta accreta: The adherent or invasive placenta. Am. J. Obstet. Gynecol. 1966, 95, 660–668. [Google Scholar] [CrossRef] [Scilit]
- Jauniaux, E.; Ayres-de-Campos, D.; Langhoff-Roos, J.; Fox, K.A.; Collins, S. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int. J. Gynaecol. Obstet. 2019, 146, 20–24. [Google Scholar] [CrossRef] [Scilit]
- Li, H.T.; Hellerstein, S.; Zhou, Y.B.; Liu, J.M.; Blustein, J. Trends in Cesarean Delivery Rates in China, 2008-2018. JAMA 2020, 323, 89–91. [Google Scholar] [CrossRef] [Scilit]
- Jahnke, J.R.; Houck, K.M.; Bentley, M.E.; Thompson, A.L. Rising rates of cesarean delivery in Ecuador: Socioeconomic and institutional determinants over two decades. Birth 2019, 46, 335–343. [Google Scholar] [CrossRef] [Scilit]
- Plevani, C.; Incerti, M.; Del Sorbo, D.; Pintucci, A.; Vergani, P.; Merlino, L.; Locatelli, A. Cesarean delivery rates and obstetric culture—An Italian register-based study. Acta Obstet. Gynecol. Scand. 2017, 96, 359–365. [Google Scholar] [CrossRef] [Scilit]
- Betrán, A.P.; Ye, J.; Moller, A.B.; Zhang, J.; Gülmezoglu, A.M.; Torloni, M.R. The Increasing Trend in Caesarean Section Rates: Global, Regional and National Estimates: 1990–2014. PLoS ONE 2016, 11, e0148343. [Google Scholar] [CrossRef] [Scilit]
- Wu, S.; Kocherginsky, M.; Hibbard, J.U. Abnormal placentation: Twenty-year analysis. Am. J. Obstet. Gynecol. 2005, 192, 1458–1461. [Google Scholar] [CrossRef] [Scilit]
- Jauniaux, E.; Jurkovic, D. Placenta accreta: Pathogenesis of a 20th century iatrogenic uterine disease. Placenta 2012, 33, 244–251. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Baldwin, H.J.; Patterson, J.A.; Nippita, T.A.; Torvaldsen, S.; Ibiebele, I.; Simpson, J.M.; Ford, J.B. Antecedents of Abnormally Invasive Placenta in Primiparous Women: Risk Associated with Gynecologic Procedures. Obstet. Gynecol. 2018, 131, 227–233. [Google Scholar] [CrossRef] [Scilit]
- O’Brien, J.M.; Barton, J.R.; Donaldson, E.S. The management of placenta percreta: Conservative and operative strategies. Am. J. Obstet. Gynecol. 1996, 175, 1632–1638. [Google Scholar] [CrossRef] [Scilit]
- Silver, R.M.; Landon, M.B.; Rouse, D.J.; Leveno, K.J.; Spong, C.Y.; Thom, E.A.; Moawad, A.H.; Caritis, S.; Harper, M.; Wapner, R.J.; et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet. Gynecol. 2006, 107, 1226–1232. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jauniaux, E.; Alfirevic, Z.; Bhide, A.G.; Belfort, M.A.; Burton, G.J.; Collins, S.L.; Dornan, S.; Jurkovic, D.; Kayem, G.; Kingdom, J.; et al. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. Bjog 2019, 126, e1–e48. [Google Scholar] [CrossRef] [Scilit]
- Cahill, A.G.; Beigi, R.; Heine, P.; Silver, R.; Wax, J.R. Obstetric Care Consensus No. 7 Summary: Placenta Accreta Spectrum. Obstet. Gynecol. 2018, 132, 1519–1521. [Google Scholar]
- Jauniaux, E.; Bhide, A.; Kennedy, A.; Woodward, P.; Hubinont, C.; Collins, S. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int. J. Gynaecol Obstet. 2018, 140, 274–280. [Google Scholar] [CrossRef] [Scilit]
- Hobson, S.R.; Kingdom, J.C.; Murji, A.; Windrim, R.C.; Carvalho, J.C.; Singh, S.S.; Ziegler, C.; Birch, C.; Frecker, E.; Lim, K.; et al. No. 383-Screening, Diagnosis, and Management of Placenta Accreta Spectrum Disorders. J Obstet. Gynaecol. Can. 2019, 41, 1035–1049. [Google Scholar] [CrossRef] [Scilit]
- Calì, G.; Timor-Trisch, I.E.; Palacios-Jaraquemada, J.; Monteaugudo, A.; Forlani, F.; Minneci, G.; Foti, F.; Buca, D.; Familiari, A.; Scambia, G.; et al. Changes in ultrasonography indicators of abnormally invasive placenta during pregnancy. Int. J. Gynaecol. Obstet. 2018, 140, 319–325. [Google Scholar] [CrossRef] [Scilit]
- Comstock, C.H.; Lee, W.; Vettraino, I.M.; Bronsteen, R.A. The early sonographic appearance of placenta accreta. J. Ultrasound Med. 2003, 22, 19–23; quiz 4–6. [Google Scholar] [CrossRef] [Scilit]
- D’Antonio, F.; Timor-Tritsch, I.E.; Palacios-Jaraquemada, J.; Monteagudo, A.; Buca, D.; Forlani, F.; Minneci, G.; Foti, F.; Manzoli, L.; Liberati, M.; et al. First-trimester detection of abnormally invasive placenta in high-risk women: Systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018, 51, 176–183. [Google Scholar] [CrossRef] [Scilit]
- Collins, S.L.; Ashcroft, A.; Braun, T.; Calda, P.; Langhoff-Roos, J.; Morel, O.; Stefanovic, V.; Tutschek, B.; Chantraine, F.; on behalf of the European Working Group on Abnormally Invasive Placenta (EW-AIP). Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). Ultrasound Obstet. Gynecol. 2016, 47, 271–275. [Google Scholar] [CrossRef] [Scilit]
- D’Antonio, F.; Iacovella, C.; Bhide, A. Prenatal identification of invasive placentation using ultrasound: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2013, 42, 509–517. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rac, M.W.; Dashe, J.S.; Wells, C.E.; Moschos, E.; McIntire, D.D.; Twickler, D.M. Ultrasound predictors of placental invasion: The Placenta Accreta Index. Am. J. Obstet. Gynecol. 2015, 212, 343.e1–343.e7. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gilboa, Y.; Spira, M.; Mazaki-Tovi, S.; Schiff, E.; Sivan, E.; Achiron, R. A novel sonographic scoring system for antenatal risk assessment of obstetric complications in suspected morbidly adherent placenta. J. Ultrasound Med. 2015, 34, 561–567. [Google Scholar] [CrossRef] [Scilit]
- Cali, G.; Forlani, F.; Lees, C.; Timor-Tritsch, I.; Palacios-Jaraquemada, J.; Dall’Asta, A.; Bhide, A.; Flacco, M.E.; Manzoli, L.; Labate, F.; et al. Prenatal ultrasound staging system for placenta accreta spectrum disorders. Ultrasound Obstet. Gynecol. 2019, 53, 752–760. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pagani, G.; Cali, G.; Acharya, G.; Trisch, I.-T.; Palacios-Jaraquemada, J.; Familiari, A.; Buca, D.; Manzoli, L.; Flacco, M.E.; Fanfani, F.; et al. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: A systematic review and meta-analysis. Acta Obstet. Gynecol. Scand. 2018, 97, 25–37. [Google Scholar] [CrossRef] [Scilit]
- Palacios-Jaraquemada, J.M.; Bruno, C.H.; Martín, E. MRI in the diagnosis and surgical management of abnormal placentation. Acta Obstet. Gynecol. Scand. 2013, 92, 392–397. [Google Scholar] [CrossRef] [Scilit]
- Morlando, M.; Collins, S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. Int. J. Womens Health 2020, 12, 1033–1045. [Google Scholar] [CrossRef] [Scilit]
- Karkhanis, P.; Ahmed, I.; Irani, S. Placenta accreta spectrum disorders—Detection rate and maternal outcomes following implementation of an institutional protocol. J. Obstet. Gynaecol. 2022, 42, 202–208. [Google Scholar] [CrossRef] [Scilit]
- Dwyer, B.K.; Belogolovkin, V.; Tran, L.; Rao, A.; Carroll, I.; Barth, R.; Chitkara, U. Prenatal diagnosis of placenta accreta: Sonography or magnetic resonance imaging? J. Ultrasound Med. 2008, 27, 1275–1281. [Google Scholar] [CrossRef] [Scilit]
- Silver, R.M.; Branch, D.W. Placenta accreta spectrum. New Engl. J. Med. 2018, 378, 1529–1536. [Google Scholar] [CrossRef] [Scilit]
- Pilloni, E.; Alemanno, M.G.; Gaglioti, P.; Sciarrone, A.; Garofalo, A.; Biolcati, M.; Botta, G.; Viora, E.; Todros, T. Accuracy of ultrasound in antenatal diagnosis of placental attachment disorders. Ultrasound Obstet. Gynecol. 2016, 47, 302–307. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Jauniaux, E.; Collins, S.L.; Jurkovic, D.; Burton, G.J. Accreta placentation: A systematic review of prenatal ultrasound imaging and grading of villous invasiveness. Am. J. Obstet. Gynecol. 2016, 215, 712–721. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gulati, A.; Anand, R.; Aggarwal, K.; Agarwal, S.; Tomer, S. Ultrasound as a Sole Modality for Prenatal Diagnosis of Placenta Accreta Spectrum: Potentialities and Pitfalls. Indian J. Radiol. Imaging 2021, 31, 527–538. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Thiravit, S.; Ma, K.; Goldman, I.; Chanprapaph, P.; Jha, P.; Hippe, D.S.; Dighe, M. Role of Ultrasound and MRI in Diagnosis of Severe Placenta Accreta Spectrum Disorder: An Intraindividual Assessment with Emphasis on Placental Bulge. Am. J. Roentgenol. 2021, 217, 1377–1388. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Ishibashi, H.; Miyamoto, M.; Shinmoto, H.; Soga, S.; Matsuura, H.; Kakimoto, S.; Iwahashi, H.; Sakamoto, T.; Hada, T.; Suzuki, R.; et al. The use of magnetic resonance imaging to predict placenta previa with placenta accreta spectrum. Acta Obstet. Gynecol. Scand. 2020, 99, 1657–1665. [Google Scholar] [CrossRef] [Scilit]
- Jha, P.; Rabban, J.; Chen, L.M.; Goldstein, R.B.; Weinstein, S.; Morgan, T.A.; Shum, D.; Hills, N.; Ohliger, M.A.; Poder, L. Placenta accreta spectrum: Value of placental bulge as a sign of myometrial invasion on MR imaging. Abdom. Radiol. 2019, 44, 2572–2581. [Google Scholar] [CrossRef] [Scilit]
- Tinari, S.; Buca, D.; Cali, G.; Timor-Tritsch, I.; Palacios-Jaraquemada, J.; Rizzo, G.; Lucidi, A.; Di Mascio, D.; Liberati, M.; D’Antonio, F. Risk factors, histopathology and diagnostic accuracy in posterior placenta accreta spectrum disorders: Systematic review and meta-analysis. Ultrasound Obstet. Gynecol. 2021, 57, 903–909. [Google Scholar] [CrossRef] [Scilit]
- Gao, Y.; Gao, X.; Cai, J.; Han, F.; Xu, G.; Zhang, X.; Zhang, T.; Yu, L. Prediction of placenta accreta spectrum by a scoring system based on maternal characteristics combined with ultrasonographic features. Taiwan. J. Obstet. Gynecol. 2021, 60, 1011–1017. [Google Scholar] [CrossRef] [Scilit]
- Romeo, V.; Verde, F.; Sarno, L.; Migliorini, S.; Petretta, M.; Mainenti, P.P.; D’Armiento, M.; Guida, M.; Brunetti, A.; Maurea, S. Prediction of placenta accreta spectrum in patients with placenta previa using clinical risk factors, ultrasound and magnetic resonance imaging findings. Radiol. Med. 2021, 126, 1216–1225. [Google Scholar] [CrossRef] [Scilit]
- Morel, O.; van Beekhuizen, H.J.; Braun, T.; Collins, S.; Pateisky, P.; Calda, P.; Henrich, W.; Al Naimi, A.; Norgaardt, L.N.; Chalubinski, K.M.; et al. Performance of antenatal imaging to predict placenta accreta spectrum degree of severity. Acta Obstet. Gynecol. Scand. 2021, 100, 21–28. [Google Scholar] [CrossRef] [Scilit]
- Delli Pizzi, A.; Tavoletta, A.; Narciso, R.; Mastrodicasa, D.; Trebeschi, S.; Celentano, C.; Mastracchio, J.; Cianci, R.; Seccia, B.; Marrone, L.; et al. Prenatal planning of placenta previa: Diagnostic accuracy of a novel MRI-based prediction model for placenta accreta spectrum (PAS) and clinical outcome. Abdom. Radiol. 2019, 44, 1873–1882. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chen, T.; Xu, X.Q.; Shi, H.B.; Yang, Z.Q.; Zhou, X.; Pan, Y. Conventional MRI features for predicting the clinical outcome of patients with invasive placenta. Diagn. Interv. Radiol. 2017, 23, 173. [Google Scholar] [CrossRef] [Scilit] [PubMed]

| Patient’s Characteristics | Pas Positive (n = 26) | Pas Negative (n = 13) | p Value |
|---|---|---|---|
| Age (years, mean ± SD) | 32 ± 3.7 | 31.08 ± 4.17 | 0.49 |
| BMI (kg/m2, mean ± SD) | 30.26 ± 3.49 | 28.13 ± 1.59 | 0.044 |
| Current smoker (%) | 13 (50%) | 4 (30.76%) | 0.25 |
| Number of gestations (mean ± SD) | 3.38 ± 2.17 | 2.54 ± 1.26 | 0.20 |
| Parity (mean ± SD) | 2.96 ± 2.14 | 2.23 ± 0.72 | 0.24 |
| Previous CS (mean ± SD) | 2.3 ± 1.54 | 1.31 ± 0.63 | 0.032 |
| Gestational age at delivery (weeks, mean ± SD) | 35.77 ± 2.1 | 36.15 ± 1.21 | 0.55 |
| Birth weight (grams, mean ± SD) | 2804.6 ± 482.4 | 2963 ± 307.3 | 0.219 |
| APGAR score (mean ± SD) | 6.9 ± 1.7 | 6.7 ± 1.1 | 0.868 |
| Hospitalization (days, mean ± SD) | 4.38 ± 1.75 | 7.77 ± 2.55 | <0.01 |
| Intraoperative Outcome | Characteristics | |
|---|---|---|
| Yes (No, %) | No (No, %) | |
| Total hysterectomy | 20 (76.9%) | 6 (23.1%) |
| Subtotal hysterectomy | 6 (23.1%) | 20 (76.9%) |
| Intraoperative urinary bladder injury | 14 (53.8%) | 12 (46.2%) |
| Intraoperative ureteral injury | 7 (26.9%) | 19 (73.1%) |
| Hypogastric artery ligation | 10 (38.5%) | 16 (61.5%) |
| Necessity of blood transfusion | 7 (26.9%) | 19 (73.1%) |
| Ultrasound Signs | Pas Positive (n = 26) | Pas Negative (n = 13) | Se | Sp | Accuracy | PPV | NPV | p Value |
|---|---|---|---|---|---|---|---|---|
| Placental lacunar spaces | 24 | 3 | 92.3% (24/26) | 76.9% (7/13) | 0.87 | 88.8% (24/27) | 83.3% (10/12) | <0.001 |
| Loss of retroplacental clear zone | 24 | 7 | 92.3% (24/26) | 46.1% (7/13) | 0.76 | 77.4% (24/31) | 75% (6/8) | 0.005 |
| Bladder wall interruption | 14 | 0 | 53.8% (14/26) | 100% (13/13) | 0.69 | 100% (14/14) | 52% (13/25) | 0.001 |
| Myometrial thinning < 1 mm | 24 | 3 | 92.3% (24/26) | 76.9% (10/13) | 0.87 | 88.8% (24/27) | 83.3% (10/12) | <0.001 |
| Placental bulging | 8 | 0 | 30.7% (8/26) | 100% (13/13) | 0.53 | 100% (8/8) | 41.9% (13/31) | 0.025 |
| Bridging vessels | 21 | 1 | 80.7% (21/26) | 92.3% (12/13) | 0.84 | 95.4% (21/22) | 70.5% (12/17) | <0.001 |
| Hypervascularity of the uterovesical or retroplacental space | 11 | 1 | 42.3% (11/26) | 92.3% (12/13) | 0.58 | 91.6% (11/12) | 44.4% (12/27) | 0.027 |
| ≥3 US signs present | 22 | 1 | 84.6% (22/26) | 92.3% (12/13) | 0.87 | 95.6% (22/23) | 75% (12/16) | <0.001 |
| Ultrasound Signs | Grade I | p Value | Grade II | p Value | Grade IIIa | p Value | Grade IIIb | p Value |
|---|---|---|---|---|---|---|---|---|
| Placental lacunar spaces (OR+ CI 95%) | 0.025 (0.004–0.173) | <0.001 | 6.250 (1.145–34.123) | 0.024 | 0.647 (0.505–0.829) | 0.110 | 0.657 (0.517–0.835) | 0.159 |
| Loss of retroplacental clear zone (OR+ CI 95%) | 0.097 (0.16–0.593) | 0.005 | 7.467 (0.819–68.1) | 0.047 | 1.037 (0.1–10.806) | 0.976 | 0.771 (0.644–0.924) | 0.284 |
| Myometrial thinning < 1 mm (OR+ CI 95%) | 0.58 (0.11–0.312) | <0.001 | 6.250 (1.145–34.123) | 0.024 | 1.913 (0.191–19.198) | 0.576 | 0.657 (0.517–0.835) | 0.159 |
| Bladder wall interruption (OR+ CI 95%) | 0.083 (0.009–0.737) | 0.009 | 0.602 (0.157–2.31) | 0.458 | 9.6 (0.951–96.922) | 0.028 | 0.286 (0.169–0.482) | 0.005 |
| Bridging vessels (OR+ CI 95%) | 0.20 (0.002–0.190) | <0.001 | 2.88 (0.755–10.987) | 0.117 | 0.5 (0.357–0.7) | 0.035 | 0.514 (0.373–0.71) | 0.063 |
| Placental bulging (OR+ CI 95%) | 0.692 (0.536–0.895) | 0.025 | 0.356 (0.062–2.043) | 0.234 | 3.111 (0.423–22.866) | 0.248 | 0.114 (0.45–0.287) | < 0.001 |
| Hypervascularity of the uterovesical or retroplacental space (OR+ CI 95%) | 0.114 (0.013–1.009) | 0.027 | 0.310 (0.068–1.4) | 0.119 | 13 (1.265–133.635) | 0.011 | 0.229 (0.124–0.42) | 0.002 |
| MRI Signs | Pas Positive (n = 26) | Pas Negative (n = 13) | Sp | Sp | Accuracy | PPV | NPV | p Value |
|---|---|---|---|---|---|---|---|---|
| Intraplacental dark T2 bands | 24 | 8 | 92.3% (24/26) | 38.4% (5/13) | 0.74 | 75.% (24/32) | 71.4% (5/7) | 0.018 |
| Placental bulging | 8 | 0 | 30.7% (8/26) | 100% (13/13) | 0.53 | 100% (8/8) | 41.9% (13/31) | 0.025 |
| Loss of retroplacental hypointense line on T2 images | 25 | 5 | 96.1% (25/26) | 61.5% (8/13) | 0.84 | 83.3% (25/30) | 88.8% (8/9) | <0.001 |
| Myometrial thinning < 1 mm | 26 | 12 | 100% (26/26) | 7.69% (1/13) | 0.69 | 68.4% (26/38) | 100% (1/1) | 0.152 |
| Bladder wall interruption | 11 | 0 | 42.3% (11/26) | 100% (13/13) | 0.61 | 100% (11/11) | 46.4% (13/28) | 0.006 |
| Focal exophytic placental mass | 10 | 0 | 38.4% (10/26) | 100% (13/13) | 0.58 | 100% (10/10) | 44.8% (13/29) | 0.010 |
| Abnormal vascularization of the placental bed | 17 | 2 | 65.3% (17/26) | 84.6% (11/13) | 0.71 | 89.4% (17/19) | 63.6% (7/11) | 0.003 |
| ≥3 MRI signs present | 24 | 5 | 92.3% (24/26) | 61.5% (8/13) | 0.82 | 82.7% (24/29) | 80% (8/10) | <0.001 |
| MRI Signs | Grade I | p Value | Grade II | p Value | Grade IIIa | p Value | Grade IIIb | p Value |
|---|---|---|---|---|---|---|---|---|
| Placental bulging (OR+ CI 95%) | 0.692 (0.536–0.895) | 0.025 | 0.134 (0.15–1.221) | 0.47 | 8.7 (1.148–65.934) | 0.019 | 0.114 (0.045–0.287) | <0.001 |
| Intraplacental dark T2 bands (OR+ CI 95%) | 2.16 (1.2–3.89) | <0.001 | 0.682 (0.513–0.907) | 0.010 | 0.794 (0.669–0.942) | 0.263 | 0.8 (0.678–0.944) | 0.323 |
| Loss of retroplacental hypointense line on T2 images (OR+ CI 95%) | 0.25 (0.003–0.247) | <0.001 | 9.143 (1.014–82.442) | 0.025 | 0.735 (0.601–0.9) | 0.190 | 0.743 (0.611–0.903) | 0.248 |
| Bladder wall interruption (OR+ CI 95%) | 0.133 (0.15–1.189) | 0.044 | 0.375 (0.82–1.714) | 0.198 | 15.429 (1.481–160.76) | 0.006 | 10.125 (0.922–111.247) | 0.028 |
| Focal exophytic placental mass (OR+ CI 95%) | 0.615 (0.454–0.834) | 0.010 | 0.821 (0.190–3.539) | 0.791 | 18.667 (1.759–198.103) | 0.003 | 3.375 (0.408–27.916) | 0.239 |
| Abnormal vascularization of the placental bed (OR+ CI 95%) | 0.188 (0.041–0.851) | 0.023 | 3.208 (0.857–12.018) | 0.079 | 0.667 (0.099–4.508) | 0.676 | 3.563 (0.337–37.687) | 0.267 |
| Sign | Relative Incidence | True Predictive Value | |||
|---|---|---|---|---|---|
| PAS Positive | PAS Negative | Total | |||
| Ultrasonography signs | Placental lacunar spaces | 92.3% (24/26) | 23% (3/13) | 69.2% (27/39) | 88.8% (24/27) |
| Loss of retroplacental clear zone | 92.3% (24/26) | 53.8% (7/13) | 79.4% (31/39) | 77.4% (24/31) | |
| Myometrial thinning < 1 mm | 92.3% (24/26) | 23% (3/13) | 69.2% (27/39) | 88.8% (24/27) | |
| Bladder wall interruption | 53.8% (14/26) | 0% (0/13) | 35.9% (14/39) | 100% (14/14) | |
| Bridging vessels | 80.7% (21/26) | 7.7% (1/13) | 56.4% (22/39) | 95.4% (21/22) | |
| Placental bulging | 30.7% (8/26) | 0% (0/13) | 20.5% (8/39) | 100% (8/8) | |
| Hypervascularity of the uterovesical or retroplacental space | 42.3% (11/26) | 7.7% (1/13) | 30.7% (12/39) | 91.6% (11/12) | |
| MRI signs | Intraplacental dark T2 bands | 92.3% (24/26) | 61.5% (8/13) | 82% (32/39) | 75% (24/32) |
| Placental bulging | 30.7 % (8/26) | 0% (0/13) | 20.5% (8/39) | 100% (8/8) | |
| Loss of retroplacental hypointense line on T2 images | 96.1% (25/26) | 38.5% (5/13) | 77% (30/39) | 83.3% (25/30) | |
| Myometrial thinning < 1 mm | 100% (26/26) | 92.3% (12/13) | 97.4% (38/39) | 68.4% (26/38) | |
| Bladder wall interruption | 42.3% (11/26) | 0% (0/13) | 28.2% (11/39) | 100% (11/11) | |
| Focal exophytic placental mass | 38.4% (10/26) | 0% (0/13) | 25.6% (10/39) | 100% (10/10) | |
| Abnormal vascularization of the placental bed | 65.3% (17/26) | 15.4% (2/13) | 48.7% (19/39) | 89.4% (17/19) | |
| Surgical Outcomes | ≥3 US Signs Present | ≥3 MRI Signs Present | ||
|---|---|---|---|---|
| r | p | r | p | |
| Total hysterectomy | 0.54 | <0.001 | 0.60 | <0.001 |
| Subtotal hysterectomy | 0.21 | 0.19 | −0.07 | 0.64 |
| Intraoperative urinary bladder injury | 0.29 | 0.06 | 0.31 | 0.04 |
| Intraoperative ureteral injury | 0.25 | 0.11 | 0.12 | 0.46 |
| Hypogastric artery ligation | 0.25 | 0.12 | 0.34 | 0.03 |
| Necessity of blood transfusion | 0.11 | 0.47 | 0.27 | 0.091 |
| Days of hospitalization | 0.33 | 0.03 | 0.4 | 0.01 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Haba, R.M.; Pristavu, A.I.; Cobzeanu, M.-L.; Carauleanu, A.; Sadiye Scripcariu, I.; Vasilache, I.A.; Minciuna, D.A.; Negru, D.; Socolov, D.G. Predicting Placenta Accreta Spectrum Disorders in a Cohort of Pregnant Patients in the North-East Region of Romania—Diagnostic Accuracy of Ultrasound and Magnetic Resonance Imaging. Diagnostics 2022, 12, 2130. https://doi.org/10.3390/diagnostics12092130
Haba RM, Pristavu AI, Cobzeanu M-L, Carauleanu A, Sadiye Scripcariu I, Vasilache IA, Minciuna DA, Negru D, Socolov DG. Predicting Placenta Accreta Spectrum Disorders in a Cohort of Pregnant Patients in the North-East Region of Romania—Diagnostic Accuracy of Ultrasound and Magnetic Resonance Imaging. Diagnostics. 2022; 12(9):2130. https://doi.org/10.3390/diagnostics12092130
Chicago/Turabian StyleHaba, Raluca Maria, Anda Ioana Pristavu, Maria-Luiza Cobzeanu, Alexandru Carauleanu, Ioana Sadiye Scripcariu, Ingrid Andrada Vasilache, Dorina Adelina Minciuna, Dragos Negru, and Demetra Gabriela Socolov. 2022. "Predicting Placenta Accreta Spectrum Disorders in a Cohort of Pregnant Patients in the North-East Region of Romania—Diagnostic Accuracy of Ultrasound and Magnetic Resonance Imaging" Diagnostics 12, no. 9: 2130. https://doi.org/10.3390/diagnostics12092130
APA StyleHaba, R. M., Pristavu, A. I., Cobzeanu, M.-L., Carauleanu, A., Sadiye Scripcariu, I., Vasilache, I. A., Minciuna, D. A., Negru, D., & Socolov, D. G. (2022). Predicting Placenta Accreta Spectrum Disorders in a Cohort of Pregnant Patients in the North-East Region of Romania—Diagnostic Accuracy of Ultrasound and Magnetic Resonance Imaging. Diagnostics, 12(9), 2130. https://doi.org/10.3390/diagnostics12092130

